These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34815785)

  • 1. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 2. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.
    Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
    J Transl Med; 2021 Aug; 19(1):352. PubMed ID: 34404444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development.
    Chen Z; Wang X; Yan Z; Zhang M
    Cancer Med; 2022 Jul; 11(13):2711-2726. PubMed ID: 35285582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of tumor-antigen signatures and immune subtypes for messenger RNA vaccine selection in advanced clear cell renal cell carcinoma.
    Xu Z; Wu Y; Chen X; Jin B
    Surgery; 2024 Sep; 176(3):785-797. PubMed ID: 38851900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic prediction and immune checkpoint profiling in glioma patients through neddylation-associated features.
    Qi J; Li L; Gao B; Dai K; Shen K; Wu X; Li H; Yu Z; Wang Z; Wang Z
    Gene; 2024 Dec; 930():148835. PubMed ID: 39127414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
    Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
    Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of m
    Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
    Front Immunol; 2022; 13():955848. PubMed ID: 36203569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
    Wang F
    Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes.
    Wu F; Liu YW; Li GZ; Zhai Y; Feng YM; Ma WP; Zhao Z; Zhang W
    Br J Cancer; 2021 Jul; 125(2):255-264. PubMed ID: 34006924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
    Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Front Immunol; 2021; 12():557994. PubMed ID: 34220791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.